New frontiers in androgen biosynthesis and metabolism

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 3, 2010, Pages 233-239

  Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 reductase; Abiraterone acetate; Aldo keto reductase; Castrate resistant prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; DUTASTERIDE; FINASTERIDE; FLUFENAMIC ACID; FLUTAMIDE; INDOMETACIN; INDOMETACIN DERIVATIVE; LEUPRORELIN; OXOSTEROID; STEROID; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TESTOSTERONE;

AGING; ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CLINICAL TRIAL; CONJUGATION; ENZYME MECHANISM; HUMAN; LIVER; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; STEREOISOMERISM; TREATMENT RESPONSE;

ALCOHOL OXIDOREDUCTASES; ANDROGENS; BIOMEDICAL RESEARCH; HUMANS; LIVER; MALE; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 77951809447     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283381a31     Document Type: Review

References (63)

1. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17b-hydroxysteroid dehydrogenase 3. Nat Genet 1994; 7:34-39.
2. Russell DW, Wilson JD. Steroid 5a-reductase two genes/two enzymes. Ann Rev Biochem 1994; 63:25-61.
3. Beg S, Al-Khoury L, Cunningham GR. Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes 2008; 15:364-370.
4. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. Rev Urol 2003; 5:216-226.
5. Labrie F, Belanger A, Simard J. Intracrinology. Autonomy and freedom of peripheral tissues. Ann Endocrinol (Paris) 1995; 56:23-29.
6. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17bhydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000; 25:1-16.
7. Kondo K, Kai M, Setoguchi Y, et al. Cloning and expression of cDNA of human D4-3-oxosteroid-5b-reductase and substrate specificity of the expressed enzyme. Eur J Biochem 1994; 219:357-363.
8. Penning TM, Burczynski ME, Jez JM, et al. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351:67-77.
9. Steckelbroeck S, Jin Y, Gopishetty S, et al. Human cytosolic 3a-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3b-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 2003; 279:10784-10795.
10. Di Costanzo L, Drury J, Penning TM, Christianson DW. Crystal structure of human liver D4-3-ketosteroid 5b-reductase (AKR1D1) and implications for substrate binding and catalysis. J Biol Chem 2008; 283:16830-16839.
11. Di Costanzo L, Drury J, Christianson DW, Penning TM. Structure and catalytic mechanism of human steroid 5b-reductase (AKR1D1). Mol Cell Endocrinol 2009; 301:191-198.
12. Drury JE, Di Constanzo L, Penning TM, Christianson DW. Inhibition of human steroid 5b-reductase (AKR1D1) by finasteride and structure of the enzyme- inhibitor complex. J Biol Chem 2009; 284:19786-19790.
13. Faucher F, Cantin L, Luu-The V, Breton R. The crystal structure of human D4-3- ketosteroid 5b-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. Biochemistry 2008; 47:8261-8270.
14. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998; 95:12208-12213.
15. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000; 275:15122-15127.
16. Huskey SW, Dean DC, Miller RR, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 1995; 23:1126-1135.
17. Jin Y, Duan L, Lee SH, et al. Human cytosolic hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. J Biol Chem 2009; 284:10013-10022.
18. Bé langer A, Pelletier G, Labrie F, et al. Inactivation of androgens by UDPglucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14:473-479.
19. Hochberg RB, Ladany S, Welch M, Liebermann S. Cholesterol and cholesterol sulfate as substrates for the adrenal side-chain cleavage enzyme. Biochemistry 1974; 13:1938-1945.
20. Jacobsohn GM, Hochberg RB. 17b-Hydroxysteroid dehydrogenase from human red blood cells. J Biol Chem 1968; 243:2985-2994.
21. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002; 62:1784-1789.
22. Simard J, Ricketts ML, Gingras S, et al. Molecular biology of the 3b-hydroxysteroid dehydrogenase/5-4 isomerase gene family. Endocrine Rev 2005; 26:525-582.
23. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 2006; 147:5806-5816.
24. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3ahydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13:169-180.
25. Lin HK, Steckelbroeck S, Fung KM, et al. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase): immunohistochemical detection in breast and prostate. Steroids 2004; 69:795-801.
26. Penning TM, Steckelbroeck S, Bauman DR, et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248:182-191.
27. Thomas LN, Douglas RC, Lazier CB, et al. Type 1 and type 2 5a-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53:244-252.
28. Jin Y, Penning TM. Multiple steps determine the overall rate of the reduction of 5a-dihydrotestosterone catalyzed by human type 3 3a-hydroxysteroid dehydrogenase: implications for the elimination of androgens. Biochemistry 2006; 45:13054-13063.
29. Rizner T, Lin H-K, Peehl DM, et al. Human type 3 3a-hydroxysteroid dehydrogenase (AKR1C2) and androgen metabolism in prostate cells. Endocrinology 2003; 144:2922-2932.
30. Barbier O, Belanger A. Inactivation of androgens by UDP- glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008; 22:259-270.
31. Lin HK, Jez J, Schlegel BP, et al. Expression and characterization of recombinant type 2 3a-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997; 11:1971-1984.
32. Montgomery RB, Mostaghel E, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
33. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004; 6 (Suppl 9):S31-S39.
34. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERb, AR, 5a-androstane-3b,17b-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A 2002; 99:13589-13594.
35. Weihua Z, Makela S, Andersson LC, et al. A role for estrogen receptor b in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 2001; 98:6330-6335.
36. Jacobi GH, Moore RJ, Wilson JD. Studies on the mechanism of 3a-androstanediol- induced growth of the dog prostate. Endocrinology 1978; 102:1748-1758.
37. Shaw G, Renfree M, Leihy MW, et al. Prostate formation in a marsupial is mediated by the testicular androgen 5a-androstane-3a,17b-diol. Proc Natl Acad Sci U S A 2000; 97:12256-12259.
38. Wilson JD, Auchus R, Leihy MW, et al. 5a-Androstane-3a,17b-diol is formed in tammar wallaby pouch young testes by a pathway involving 5a-pregnane- 3a,17a-diol-20-one as a key intermediate. Endocrinology 2003; 144:575-580.
39. Horst HJ, Dennis M, Kaufmann J, Voigt KD. In vivo uptake and metabolism of 3-h 5a-androstane-3a,17b-diol and of 3-h 5a-androstane-3b,17b-diol by human prostatic hypertrophy. Acta Endocrinol (Copenh) 1975; 79:394-402.
40. Bauman DR, Steckelbroeck S, Williams MV, et al. Identification of the major oxidative 3a-hydroxysteroid dehydrogenase in human prostate that converts 5a-androstane-3a,17b-diol to 5a-dihydrotestosterone: a potential therapeutic target for androgen dependent disease. Mol Endocrinol 2006; 20:444-458.
41. Auchus R. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15:432-438.
42. Ghayee HK, Auchus R. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 2007; 8:289-300.
43. Penning TM, Bauman D, Jin Y, Rizner TL. Identification of the molecular switch that regulates access of 5a-DHT to the androgen receptor. Mol Cell Endocrinol 2007; 265-266:77-82.
44. Penning TM, Jin Y, Rizner TL, Bauman DR. Prereceptor regulation of the androgen receptor. Mol Cell Endocrinol 2008; 281:1-8.
45. Rittmaster R. 5a-Reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008; 22:389-402.
46. Schwinn DA, Roehrborn C. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15:193-199.
47. Oefelein M. Time to normalization of serum testosterone after 3-month leutenizing hormone releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998; 160:1685-1688.
48. Tran C, Ouk S, Clegg NJ, et al. Development of a second generation antiandrogen for the treatment of advanced prostate cancer. Science 2009; 324:787-790.
49. Attar RM, Takimoto C, Gottardis MM. Castration-resistant prostate cancer: lockingupthemolecularescaperoutes.ClinCancerRes2009;15:3251-3255.
50. Knudsen KE, Scher H. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15:4792-4798.
51. Yuan X, Balk S. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27:36-41.
52. Locke J, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during the progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407-6415.
53. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825.
54. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
55. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
56. Leon CG, Locke JA, Adomat HH, et al. Alteration in cholesterol regulation contribute to the production of intra-tumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2009 [Epub ahead of print].
57. Locke JA, Nelson CC, Adomat HH, et al. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115:126-136.
58. Locke J, Guns EST, Lehman ML, et al. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2009; 70:239-251.
59. Hille UE, Hu Q, Vock C, et al. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur J Med Chem 2009; 44:2765-2775.
60. Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17a-hydroxylase/17,20-lyase inhibitor 3bhydroxy- 17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008; 7:2348-2357.
61. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4- chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3a-HSD, type 5 17b-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008; 75:484-493.
62. Bauman DR, Rudnick S, Szewczuk L, et al. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 2005; 67:60-68.
63. Féau C, Arnold L, Kosinski A, et al. Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem Biol 2009; 4:834-843.